A new class of cholesterol-fighting drugs could be coming to patients in the not-so-distant future, and experts say they could be a real game-changer in Americans’ battle to lower artery-clogging LDL, or “bad,” cholesterol. Elliott Antman, HMS associate dean for clinical and translational research and professor of medicine at Brigham and Women’s Hospital, is quoted.
